Short-acting Beta Agonists Market Size

Short-acting Beta Agonists Market size is expected to reach USD 2.07 Billion by the end of 2036, growing at a CAGR of 9% during the forecast period, i.e. 2024-2036. In the year 2023, the industry size of short-acting beta agonists was USD 736 Million. The escalating prevalence of respiratory disorders worldwide is propelling the market’s growth. With 454.6 million cases (417.4–499.1) worldwide, chronic respiratory disorders ranked as the third most common cause of mortality in 2019. They were responsible for 4.0 million deaths (95% uncertainty interval 3.6–4.3) worldwide. As conditions like asthma and chronic obstructive pulmonary disease(COPD) become more widespread, the demand for quick-relief medications, such as SABAs, continues to surge. As observed by Research Nester analysts, globally, the prevalence of COPD was predicted to be 10.6% in 2020 for both males and females, or 480 million cases. This driver is fuelled by environmental factors, lifestyle changes, and an aging population, necessitating effective bronchodilators for immediate symptom relief. As a result, pharmaceutical companies are witnessing increased demand for SABAs, positioning them as a pivotal solution in addressing the rising global burden of respiratory diseases.

In addition, when it comes to death rates, chronic obstructive pulmonary disease (COPD) is ranked third worldwide. The increasing prevalence of lung illnesses worldwide is predicted to drive short-acting beta agonists market expansion. People who currently reside in or were raised in urban regions are more prone to experience these illnesses.